Prenetics Global (PRE) news
Recent news
Prenetics Global Ltd: B. Riley initiates coverage with buy rating; target price $37
B. Riley Securities has initiated coverage on Prenetics Global Limited (NASDAQ: PRE) with a "buy" rating and a target price of $37 per share. The move comes as the company continues to demonstrate strong performance relative to broader market benchmarks. Year-to-date through August 26, 2026,…
AInvest Wire · 4d agoPrenetics Global Q2 revenue USD 46.5 million
AInvest Wire · Aug 18, 2026Prenetics Global Ltd: Benchmark raises target price to $40 from $30
AInvest Wire · Jul 15, 2026Prenetics Global - IM8 expected to reach $300 mln annualized run-rate revenue by year-end 2026
Prenetics Global has outlined an ambitious growth trajectory for its IM8 business, with projections indicating that the segment could achieve an annualized run-rate revenue of $300 million by the end of 2026. This forecast reflects the company’s strategic focus on expanding its genomic testing and…
AInvest Wire · Jul 14, 2026Prenetics Global Ltd: IM8 expected to deliver $400 million or more in full-year 2027 revenue
AInvest Wire · Jul 14, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.